Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2003
11/18/2003US6649626 Stimulants of gamma -aminobutyric acid receptors; psychological disorders
11/18/2003US6649625 Agent for prophylaxis and treatment of glaucoma
11/18/2003US6649622 Treating diabetes, especially Type II diabetes
11/18/2003US6649621 Administering antioxidants, adensosine agonists, trophic factors, N-methyl-aspartic acid antagonists and steroids
11/18/2003US6649620 Quinoline and quinazoline compounds useful in therapy
11/18/2003US6649619 Compounds
11/18/2003US6649617 Treatment for stroke management
11/18/2003US6649616 For therapy and prophylaxis of cardiovascular disorders caused by ischaemia
11/18/2003US6649615 Alpha-adrenergic receptor antagonism using such as prazosin
11/18/2003US6649614 Psychological disorders
11/18/2003US6649613 Diacylhydrazine derivatives
11/18/2003US6649612 Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them
11/18/2003US6649611 Potent and selective inhibitors of chemokine binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes).
11/18/2003US6649610 2-oxo-1, 4-benzoxazine compounds for treatment of tuberculosis
11/18/2003US6649609 Benzimidazole derivatives and pharmaceutical compositions comprising these compounds
11/18/2003US6649608 Cyclin-dependent serine/threonine and focal adhesion kinase inhibitors
11/18/2003US6649607 Compositions and methods for treating or preventing convulsions or seizures
11/18/2003US6649606 Treating inflammatory diseases
11/18/2003US6649605 Administering amount of agent effective to interact with neuronal transmission connected with pain perception, so as to prevent or reduce central sensitization
11/18/2003US6649604 Analgesics; antidiabetic agents; antiinflamamtory agents
11/18/2003US6649603 For therapy of metabolic disorders related to insulin resistance or hyperglycemia
11/18/2003US6649602 Vernal keratoconjunctivitis, giant papillary conjunctivitis, atopic keratoconjunctivitis
11/18/2003US6649601 Bisphosphonic compound
11/18/2003US6649600 2,6-Dioxo or dithioxy-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo derivatives; highly potent and selective diuretics
11/18/2003US6649597 Delivery vehicle construct which specifically binds to and stimulates endocytosis into cells expressing the activator
11/18/2003US6649594 Compositions for metabolic protection and repair of lips
11/18/2003US6649591 Dithiocarbamates linked to the surface of a non-immunogenic, non-targeting macromolecule other than an antibody (e.g., albumin protein); treating cerebral stroke and other ischemia/reperfusion injury
11/18/2003US6649589 Blocking tumor necrosis factor activity with soluble cytokine receptor, monoclonal antibody or tetracycline derivative
11/18/2003US6649391 Isolated polynucleotide encoding a polypeptide of given sequence; dephosphorylates MAP(mitogen activated protein)-kinase; used for modulating cell proliferation, differentiation and survival
11/18/2003US6649375 Adenoviral vectors for enhanced gene expression
11/18/2003US6649366 Methods and compositions related to modulators of annexin and cartilage homeostasis
11/18/2003US6649345 Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders
11/18/2003US6649195 Eyesight enhanced maintenance composition
11/18/2003US6649193 Biomedically acceptable, cage-like compounds, including cobalamin (vitamin B12), potassium silicate and colloidal silicates and aluminosilicates such as zeolites encage atomic hydrogen in a
11/18/2003US6649187 For administering an amine drug such as (S-(R,S))-2-(4-(((4-methyl)piperazin-1-yl) carbonyl)phenoxy)-3,3-diethyl-N-(1-(3,4-methylenedioxyphenyl) butyl)-4-oxo-1-azetidinecarboxamide)
11/18/2003US6649186 Effervescent granules and methods for their preparation
11/18/2003US6649183 Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron
11/18/2003US6649157 Treating a Ras-mediated cell proliferative disorder in a mammal, by administering a modified adenovirus, modified HSV, modified vaccinia virus or modified parapoxvirus orf virus resulting in lysis of the proliferating cells.
11/18/2003US6649147 Delivery system for oral care compositions comprising organosiloxane resins using a removable backing strip
11/18/2003CA2285490C Composition for improvement of cellular nutrition and mitochondrial energetics
11/18/2003CA2274680C Process for manufacturing ophthalmic suspensions
11/18/2003CA2264155C N6 heterocyclic substituted adenosine derivatives
11/18/2003CA2136071C 2-arylpropionic acid compositions and process for preparing the same
11/18/2003CA2127472C New adenosine derivatives, preparation methods and pharmaceutical compositions containing them
11/18/2003CA2072233C Triazolopyrimidine derivatives which are angiotensin ii receptor antagonists; processes for preparing them and pharmaceutical compositions containing them
11/18/2003CA2032748C Method of inhibiting the activity of human immunodeficiency virus (hiv) in vivo
11/17/2003CA2429097A1 Composition of solutions for organ protection
11/17/2003CA2386759A1 Therapeutic uses of peroxometallic compounds
11/16/2003CA2404924A1 Composition and method for treating hypertension
11/16/2003CA2386648A1 Compositions and methods for managing bacterial skin conditions
11/14/2003CA2428516A1 Slowly digestible starch product
11/14/2003CA2428514A1 Resistant starch prepared by isoamylase debranching of low amylose starch
11/13/2003WO2003093503A2 Method for bioequivalence determination using expression profiling
11/13/2003WO2003093499A2 Therapeutic use of selective pde10 inhibitors
11/13/2003WO2003093498A1 Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic
11/13/2003WO2003093478A1 Immunoconjugates for the treatment of tumours
11/13/2003WO2003093456A1 Soya cell strains with high isoflavone content
11/13/2003WO2003093410A2 Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells
11/13/2003WO2003093409A2 Promoters exhibiting endothelial cell specificity and methods of using same
11/13/2003WO2003093322A2 Carrageenan based antimicrobial compositions
11/13/2003WO2003093297A2 Protein kinase modulators and methods of use
11/13/2003WO2003093292A1 17α-FLUOROALKYL-11β-BENZALDOXIME-STEROIDS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING SAID STEROIDS AND THE USE THEREOF IN THE PRODUCTION OF MEDICAMENTS
11/13/2003WO2003093290A2 Nucleoside derivatives for treating hepatitis c virus infection
11/13/2003WO2003093289A1 Tricyclic macrolide antibacterial compounds
11/13/2003WO2003093288A1 Antibacterial compounds with improved pharmacokinetic profiles
11/13/2003WO2003093281A1 Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1h-imidazol-1-yl)methyl]-4h-carbazol-4-one
11/13/2003WO2003093280A1 Heterotricyclyl 6-alkylidene-penems as βετα-lactamase inhibitors
11/13/2003WO2003093279A1 BICYCLIC 6-ALKYLIDENE-PENEMS AS ß-LACTAMASES INHIBITORS
11/13/2003WO2003093274A1 Camptothecin-taxoid conjugates as antimitotic and antitumor agents
11/13/2003WO2003093272A1 Imidazo-triazine derivatives as ligands for gaba receptors
11/13/2003WO2003093270A1 5-ethyl-imidazo (5,1-f) (1,2,4,) triazin-4 (3h) -ones as phosphodiesterase inhibitors
11/13/2003WO2003093268A1 7-aminoimidazotriazones
11/13/2003WO2003093267A1 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
11/13/2003WO2003093263A1 Substituted imidazole derivatives: gabaa receptor ligands
11/13/2003WO2003093260A1 Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
11/13/2003WO2003093254A1 Semicarbazide derivatives for combating thromboembolic diseases
11/13/2003WO2003093252A1 Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase
11/13/2003WO2003093249A1 Thiazolidinones and the use thereof as polo-like kinase inhibitors
11/13/2003WO2003093248A1 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
11/13/2003WO2003093245A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists
11/13/2003WO2003093243A1 Preparations for the topical application of anti-androgenically active substances
11/13/2003WO2003093242A2 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
11/13/2003WO2003093241A1 Process for the preparation of 7-substituted-3-quinoline and 3-quinol-4-one carbonitriles
11/13/2003WO2003093240A1 Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
11/13/2003WO2003093238A1 Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
11/13/2003WO2003093237A1 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors
11/13/2003WO2003093235A1 Carboxylic acid amides
11/13/2003WO2003093234A1 Melanocortin receptor ligands
11/13/2003WO2003093231A2 Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity
11/13/2003WO2003093227A1 Tamsulosin derivative
11/13/2003WO2003093222A1 Novel form of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine
11/13/2003WO2003093220A1 Process for preparing highly functionalized y-butyrolactams and y-amino acids
11/13/2003WO2003093217A1 Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
11/13/2003WO2003092791A2 Energetically-controlled delivery of biologically active material from an implanted medical device
11/13/2003WO2003092790A2 Methods for increasing the therapeutic response to electroconvulsive therapy ('ect')
11/13/2003WO2003092767A2 A method for inhibiting platelet aggregation
11/13/2003WO2003092741A1 Delivery of microparticle-conjugated drugs for inhibition of stenosis
11/13/2003WO2003092740A1 Non-viral gene delivery system
11/13/2003WO2003092739A1 Non-viral gene delivery system
11/13/2003WO2003092737A1 Fusions of cytokines and tumor targeting proteins
1 ... 5274 5275 5276 5277 5278 5279 5280 5281 5282 5283 5284 5285 5286 5287 5288 5289 5290 5291 5292 5293 5294 ... 7860